IPIRA Impact
Faster, More, Better, Creative
Deals that make sense, don't get us in trouble, and uphold our mission and principles
-
"Preferred partner" —Dow
-
"One of five best" —Inc. Magazine
-
"Breakthrough business model" —National Academy of Sciences Institute of Medicine
-
Deal of Distinction —Licensing Executives Society
-
Patents for Humanity award —US Patent and Trademark Office
-
Legacy Award 2016 —East Bay Economic Development
-
Highest Number of Startups Formed Among Universities — Pitchbook
- Second Highest Number of Entrepreneurs — PitchBook
in Funds raised
including more than $1 Billion in Industry Sponsored Research and over $250M in Licensing Revenue.
Products commercialized
from discoveries licensed through IPIRA such as of treatment for malaria and cancer, biofuels, robotic legs, DNA sequencing, surgical tools, forensic tools, handheld diagnostics, gene editing, mobile microscopy, nanowires, RFID, internet security software, search engines and more.
Startups founded
to commercialize inventions and copyrights under licenses from IPIRA, attracting almost $26B in venture funding and $51M in SBIR/STTR grants since 2005. 69 Startups have had a successful exit, of which 45 startups exited via merger or acquisition, totaling $8.1B in cash and stock options, and 24 startups exited through an IPO. 66 Berkeley startups currently in the Bay Area employ 1,543 Californians & generate $195M in annual revenue.
Companies served
through negotiated agreements with IPIRA, including $500M in industry sponsored research from BP for the Energy Biosciences Institute, >$5M in industry sponsored research from Aduro, and $89M in licensing revenue from Bristol-Myers Squibb.
gender and age, CEO gender and age, diversity, gender and age, CEO gender and age, diversity, gender and age, CEO gender and age, diversity
News about companies born out of licensing UC Berkeley intellectual property rights
